구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ramucirumab |
Overview Company | Eli Lilly and Company |
Overview Modality | ANTIBODY |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer |
Positioning Known limitation | resistance to VEGFR2 blockade |
MoA Mechanism | targets vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers exist to predict therapeutic response |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Safety signal | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Selected reported efficacy | ORR 37.5% |
Clinical Reported ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT04499924 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04499924 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ramucirumab |
Overview Company | Eli Lilly and Company |
Overview Modality | ANTIBODY |
Overview Target | Non-Small Cell Lung Cancer |
Overview Indication | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer |
Positioning Known limitation | resistance to VEGFR2 blockade |
MoA Mechanism | targets vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers exist to predict therapeutic response |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Safety signal | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Selected reported efficacy | ORR 37.5% |
Clinical Reported ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT04499924 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04499924 |
추천 비교
추천 비교